Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 13/20 | 0.62 |
| ▸ | ECE1 | P42892 | 1/20 | 0.61 |
| ▸ | MUS81 | Q96NY9 | 1/20 | 0.61 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.61 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.61 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.59 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.57 |
| ▸ | NPBWR1 | P48145 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29443914 | 0.98 | GLP1R (0.61) | GLP1RECE1MUS81OPRM1OPRD1 | |
| SCHEMBL30690352 | 0.98 | GLP1R (0.62) | GLP1RECE1MUS81OPRM1OPRD1 | |
| SCHEMBL30690338 | 0.98 | GLP1R (0.62) | GLP1RECE1MUS81OPRM1OPRD1 | |
| SCHEMBL30690385 | 0.97 | OPRM1 (0.61) | GLP1RECE1MUS81OPRM1OPRD1 | |
| SCHEMBL30690390 | 0.96 | GLP1R (0.61) | GLP1RECE1MUS81OPRM1OPRD1 | |
| SCHEMBL29443919 | 0.95 | OPRM1 (0.63) | GLP1RECE1MUS81OPRM1OPRD1 | |
| SCHEMBL30690322 | 0.94 | OPRM1 (0.63) | GLP1RECE1MUS81OPRM1OPRD1 | |
| SCHEMBL30690379 | 0.93 | OPRD1 (0.60) | GLP1RECE1MUS81OPRM1OPRD1 | |
| SCHEMBL30690372 | 0.93 | GLP1R (0.66) | GLP1RECE1MUS81OPRD1 | |
| SCHEMBL30690358 | 0.93 | GLP1R (0.66) | GLP1RECE1MUS81OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11806365-B2 | Modified T lymphocytes comprising a CD52 antibody-inducible caspase and methods of apoptosis | CELGENE CORPORATION (US) | 2023-11-07 | — | — | US | disclosed |
| US-20220324991-A1 | BCMA-BINDING ANTIBODIES AND USES THEREOF | CELGENE CORPORATION | 2022-10-13 | — | — | US | disclosed |
| US-11401336-B2 | BCMA-binding antibodies and uses thereof | CELGENE CORPORATION (US) | 2022-08-02 | — | — | US | disclosed |
| US-20220106404-A1 | CHIMERIC ANTIGEN RECEPTORS | CELGENE CORPORATION | 2022-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220324991-A1 | BCMA-BINDING ANTIBODIES AND USES THEREOF | CD79B, BCL6, CD22 | GLP1R 4654/4885ECE1 2117/4885MUS81 2045/4885 |
| US-11401336-B2 | BCMA-binding antibodies and uses thereof | CD79B, BCL6, CD22 | GLP1R 4654/4885ECE1 2117/4885MUS81 2045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.